Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has issued an update.
Fusen Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration of the PRC for the consistency evaluation of its Nicardipine Hydrochloride Injection. This product, used for emergency management of perioperative hypertension, has seen significant sales growth in China, reflecting its efficacy and market acceptance. The approval enhances Fusen’s product offerings, positioning it strongly within the market for hypertensive emergency treatments.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands with a focus on the pharmaceutical industry. It specializes in developing and producing medications, with a particular emphasis on products for managing hypertension and hypertensive emergencies.
Average Trading Volume: 2,571,358
Technical Sentiment Signal: Buy
Current Market Cap: HK$580.8M
See more data about 1652 stock on TipRanks’ Stock Analysis page.